12.14
+4.75%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zevra Therapeutics
From its filings with the US Securities and Exchange Commission
Zevra Therapeutics is based in Boston, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ZVRA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $106.5m and net income of $83.2m. At that date it held total assets of $284.7m and shareholders' equity of $154.7m.
We are a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. We are focused on expanding patient access, progressing our pipeline toward key milestones, and delivering meaningful therapeutics. Our vision is realized through disciplined execution of our strategic plan and our core values — patient centricity, integrity, accountability, innovation, and courage — which guide our efforts to deliver long-term value. The commercialization of our lead product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and demonstrates our ability to advance therapies from development to market.
In February 2023, we changed our name to Zevra Therapeutics, Inc. Zevra, is the Greek word for zebra, which is the internationally recognized symbol for rare disease. This name reflects our intense focus and dedication to developing transformational, patient-focused therapies for rare diseases with limited or no treatment options available, or treatment areas with significant unmet needs.
Quoted from its 10-K, filed 9 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 16 Apr 2015
- Employees
- 61
- Website
- kempharm.com ↗
- Head office
- 101 FEDERAL STREET, BOSTON, MA, 02110
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Ms. Tamara FavoritoIndependent Chairman of the Board$364,973
- Mr. Neil McfarlanePresident, Chief Executive Officer, Director, since 2023$5.4m
- Mr. R. LaDuane CliftonChief Financial Officer, Treasurer$1.5m
- Mr. Joshua SchaferExecutive Vice President - Business Development, Chief Commercial Officer$1.8m
- Mr. Rahsaan ThompsonChief Legal Officer, Secretary, Compliance Officer
- Dr. Adrian QuartelChief Medical Officer$2.5m
- Mr. Thomas AndersonIndependent Director$237,585
- Mr. John BodeIndependent Director$241,942
- Mr. Douglas CalderIndependent Director$228,156
- Dr. Wendy DixonIndependent Director$231,013
- Dr. Alvin ShihIndependent Director$559,160
- Mr. Corey WattonIndependent Director$236,442
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 24
- Environment
- 27
- Social
- 17
- Governance
- 29
- Carbon reduction policy
- No
- Human rights policy
- No
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.